Document is current
Any future updates will be listed below
-
Authors
Roell, Lukas
Maurus, Isabel
Schmitt, Andrea
Falkai, Peter
- License Information
-
More Information
Article History
Received: 19 August 2025
Accepted: 23 August 2025
First Online: 17 September 2025
Conflict of interest
: A. Schmitt was an honorary speaker for TAD Pharma and Roche and a member of Roche advisory boards. P. Falkai is a co-editor of the German (DGPPN) schizophrenia treatment guidelines and a co-author of the WFSBP schizophrenia treatment guidelines; he is on the advisory boards and receives speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. L. Roell and I. Maurus declare that they have no competing interests.
